These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 19063924

  • 21. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
    Tsantrizos YS.
    Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
    [Abstract] [Full Text] [Related]

  • 22. Development of cell-based assays for in vitro characterization of hepatitis C virus NS3/4A protease inhibitors.
    Chung V, Carroll AR, Gray NM, Parry NR, Thommes PA, Viner KC, D'Souza EA.
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1381-90. PubMed ID: 15793116
    [Abstract] [Full Text] [Related]

  • 23. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.
    Ng TI, Tripathi R, Reisch T, Lu L, Middleton T, Hopkins TA, Pithawalla R, Irvin M, Dekhtyar T, Krishnan P, Schnell G, Beyer J, McDaniel KF, Ma J, Wang G, Jiang LJ, Or YS, Kempf D, Pilot-Matias T, Collins C.
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084747
    [Abstract] [Full Text] [Related]

  • 24. Screening of hepatitis C virus inhibitors using genotype 1a HCV replicon cell lines.
    Robinson M, Tian Y, Pagratis N, Delaney WE.
    Curr Protoc Microbiol; 2011 Aug; Chapter 17():Unit17.7. PubMed ID: 21805689
    [Abstract] [Full Text] [Related]

  • 25. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.
    Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, Tigges AM, Adiwijaya BS, Lin C, Kwong AD, Kieffer TL.
    J Infect Dis; 2008 Sep 15; 198(6):800-7. PubMed ID: 18637752
    [Abstract] [Full Text] [Related]

  • 26. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.
    Thomson JA, Perni RB.
    Curr Opin Drug Discov Devel; 2006 Sep 15; 9(5):606-17. PubMed ID: 17002221
    [Abstract] [Full Text] [Related]

  • 27. Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro.
    Koev G, Dekhtyar T, Han L, Yan P, Ng TI, Lin CT, Mo H, Molla A.
    Antiviral Res; 2007 Jan 15; 73(1):78-83. PubMed ID: 16945431
    [Abstract] [Full Text] [Related]

  • 28. Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors.
    Franco S, Bellido R, Aparicio E, Cañete N, García-Retortillo M, Solà R, Tural C, Clotet B, Paredes R, Martínez MA.
    J Viral Hepat; 2011 Oct 15; 18(10):e578-82. PubMed ID: 21914079
    [Abstract] [Full Text] [Related]

  • 29. Designing and analysis of a potent bi-functional aptamers that inhibit protease and helicase activities of HCV NS3.
    Umehara T, Fukuda K, Nishikawa F, Sekiya S, Kohara M, Hasegawa T, Nishikawa S.
    Nucleic Acids Symp Ser (Oxf); 2004 Oct 15; (48):195-6. PubMed ID: 17150545
    [Abstract] [Full Text] [Related]

  • 30. A review of HCV protease inhibitors.
    Chen KX, Njoroge FG.
    Curr Opin Investig Drugs; 2009 Aug 15; 10(8):821-37. PubMed ID: 19649927
    [Abstract] [Full Text] [Related]

  • 31. Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors.
    Boloor A, Hanway D, Joshi M, Winn DT, Mendez G, Walls M, Wei P, Qian F, Zhang X, Zhang Y, Hepperle ME, Li X, Campbell DA, Betancort JM.
    Bioorg Med Chem Lett; 2009 Oct 01; 19(19):5708-11. PubMed ID: 19713109
    [Abstract] [Full Text] [Related]

  • 32. [Replication of the subgenomic hepatitis C virus replicon in the presence of the NS3 protease inhibitors: a stochastic model].
    Ivanisenko NV, Mishchenko EL, Akberdin IR, Demenkov PS, Likhoshvai VA, Kozlov KN, Todorov DI, Samsonova MG, Samsonov AM, Kolchanov NA, Ivanisenko VA.
    Biofizika; 2013 Oct 01; 58(5):758-74. PubMed ID: 25481944
    [Abstract] [Full Text] [Related]

  • 33. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
    Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bös M, Cameron DR, Cartier M, Cordingley MG, Faucher AM, Goudreau N, Kawai SH, Kukolj G, Lagacé L, LaPlante SR, Narjes H, Poupart MA, Rancourt J, Sentjens RE, St George R, Simoneau B, Steinmann G, Thibeault D, Tsantrizos YS, Weldon SM, Yong CL, Llinàs-Brunet M.
    Nature; 2003 Nov 13; 426(6963):186-9. PubMed ID: 14578911
    [Abstract] [Full Text] [Related]

  • 34. Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.
    Vanwolleghem T, Meuleman P, Libbrecht L, Roskams T, De Vos R, Leroux-Roels G.
    Gastroenterology; 2007 Oct 13; 133(4):1144-55. PubMed ID: 17919490
    [Abstract] [Full Text] [Related]

  • 35. A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals.
    Franco S, Clotet B, Martínez MA.
    Virus Res; 2008 Feb 13; 131(2):260-70. PubMed ID: 18037183
    [Abstract] [Full Text] [Related]

  • 36. Genotyping and resistance profile of hepatitis C (HCV) genotypes 1-6 by sequencing the NS3 protease region using a single optimized sensitive method.
    Besse B, Coste-Burel M, Bourgeois N, Feray C, Imbert-Marcille BM, André-Garnier E.
    J Virol Methods; 2012 Oct 13; 185(1):94-100. PubMed ID: 22728274
    [Abstract] [Full Text] [Related]

  • 37. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
    He Y, King MS, Kempf DJ, Lu L, Lim HB, Krishnan P, Kati W, Middleton T, Molla A.
    Antimicrob Agents Chemother; 2008 Mar 13; 52(3):1101-10. PubMed ID: 18086851
    [Abstract] [Full Text] [Related]

  • 38. Inhibition of hepatitis C virus gene expression by small interfering RNAs using a tri-cistronic full-length viral replicon and a transient mouse model.
    Kim M, Shin D, Kim SI, Park M.
    Virus Res; 2006 Dec 13; 122(1-2):1-10. PubMed ID: 16979254
    [Abstract] [Full Text] [Related]

  • 39. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.
    Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, Hughes E, Ralston R, Tong X, Herrmann E, Zeuzem S, Sarrazin C.
    Hepatology; 2009 Dec 13; 50(6):1709-18. PubMed ID: 19787809
    [Abstract] [Full Text] [Related]

  • 40. Synthesis of new acridone derivatives, inhibitors of NS3 helicase, which efficiently and specifically inhibit subgenomic HCV replication.
    Stankiewicz-Drogoń A, Dörner B, Erker T, Boguszewska-Chachulska AM.
    J Med Chem; 2010 Apr 22; 53(8):3117-26. PubMed ID: 20337460
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.